Company / Operating Income
Idexx Laboratories Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$1.4B
FY2025
5-year range
$898.8M / $1.4B
FY2021-FY2025
Trend
+20.5%
vs FY2024
Sector context
#26 of 151
Health Care
What the data says
Idexx Laboratories's operating income of $1.4B is higher than 83% of companies in the Health Care sector (FY2025). Operating Income has increased for 3 consecutive years, from $899M in FY2022 to $1.4B in FY2025.
Based on SEC 10-K filings.
$1.4B in FY2025 with a 5-year CAGR of +14.4%. Top quartile in the Health Care sector.
Improved from $1.1B to $1.4B over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +14.8%
- 5-Year CAGR
- +14.4%
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 151This company $1.4B Sector average $716.7M
▼
+89.8% above sector average
Key checks
Key Insights
- Idexx Laboratories's operating income has grown for 3 consecutive years.
- 5-year CAGR of +14.4%, indicating consistent growth.
- In FY2025, operating income increased 20.5% year-over-year.
- Ranks #26 out of 151 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4B | +20.5% |
| FY2024 | $1.1B | +2.8% |
| FY2023 | $1.1B | +22.1% |
| FY2022 | $898.8M | -3.6% |
| FY2021 | $932.0M | +34.2% |
| FY2020 | $694.5M | +25.6% |
| FY2019 | $552.8M | +12.5% |
| FY2018 | $491.3M | +19.0% |
| FY2017 | $413.0M | +17.9% |
| FY2016 | $350.2M | +16.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026